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Abstract The c-myc oncogene product (c-Myc) is a transcrip-
tion factor that dimerizes with Max and recognizes the E-box
sequence. It plays key functions in cell proliferation, differentia-
tion and apoptosis. It is generally thought that c-Myc
transactivates genes encoding proteins essential to cell-cycle
progression by binding to the E-boxes that control them. The
functions of c-Myc are also thought to be modulated by its
associated proteins, several of which have recently been
identified. In this study, we found that c-Myc directly bound in
vivo and in vitro to the N-terminal region of human CDC6, a
component of the pre-replication complex, and that both co-
localized in cell nuclei. CDC6 bound to the C-proximal region of
c-Myc, thereby competing with Max on the E-box sequence and
changing c-Myc/Max heterodimer to a Max/Max homodimer.
In consequence, the E-box-dependent transcription activity of c-
Myc was abrogated. These results suggest that, in addition to its
DNA replication activity, CDC6 also has a role as a
transcriptional suppressor of c-Myc. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
c-Myc is a transcription factor that is thought to regulate
the expression of genes involved in the control of cell-cycle
progression (see recent reviews, [1^6]). When c-Myc is com-
plexed with Max, it recognizes the E-box sequence that con-
trols the transcription of target genes. Many candidate target
genes for c-Myc/Max have been reported based on the pres-
ence of E-boxes and other circumstantial evidence. However,
the actual target genes, controlled by c-Myc/Max in vivo,
remain poorly understood. Notably, the results of experiments
with c-myc-negative (null) Rat-1 cells showed that of the
many candidate genes for c-Myc/Max, only a few revealed a
signi¢cant change in expression pattern as a consequence of
the loss of c-Myc [6,7]. In general terms, it is thought that a
chromatin remodeling complex binds to a coactivator or co-
repressor, in order to bridge sequence-speci¢c transcription
factors and basal transcription factors (see a recent review,
[8]). In particular, Max binds to Mad, antagonizing the acti-
vation function of c-Myc [9]. Mad further binds to mSin3, a
corepressor recruited to the basal transcription factors [10]. In
contrast, the mechanism by which c-Myc transactivates the
genes in cells is not well understood. Recently, SNF5/INI1,
a component of SNF2/SWI1 of chromatin remodeling com-
plexes, was reported to bind to the C-proximal region of c-
Myc to recruit it to the basal transcription factors [11].
TRRAP, a protein related to the ATM/PI3-kinase family,
binds to the N-terminal transactivation region of c-Myc and
recruits hGCN5, which possesses histone acetyl transferase
activity [12,13]. Furthermore, TIP49 and TIP48, which pos-
sess ATPase/helicase activity, bind to the transactivation re-
gion of c-Myc [14]. All of these proteins are thought to re-
model the chromatin, in order to activate gene expression
linked to the action of c-Myc. We have recently reported
that ORC1, a component of origin recognition complexes
(ORCs) of DNA replication, competes with SNF5 for binding
to the C-terminal region of c-Myc with SFN5, thereby abro-
gating the transactivation activity of c-Myc [15]. This tran-
scription function of ORC1 has also been suggested by exper-
imental systems in yeast and Drosophila [16^20]. In addition
to the role of c-Myc as a transcription factor, an earlier study
also showed that c-Myc is co-fractionated with DNA replica-
tion proteins in human HeLa cells [21]. Proof of a replication
role of c-Myc, however, has not been obtained. In this study,
we found that CDC6, a component of pre-replication com-
plexes including ORC1, directly binds to the C-terminal do-
main of c-Myc, the region recognized by Max. CDC6 abro-
gated E-box-dependent transcription by interfering with the
formation of c-Myc/Max complexes.
2. Materials and methods
2.1. Cells
Human HeLa cells were cultured in Dulbecco’s modi¢ed Eagle’s
medium supplemented with 10% calf serum. Human HL60 cells
were cultured in RPMI 1640 medium with 10% fetal calf serum.
2.2. Plasmids
An EST clone corresponding to human CDC6, clone ID#664627,
was purchased from Genome Systems Inc. All of the plasmids used in
this study were constructed by the insertion of PCR-based ampli¢ed
fragments, starting from the ¢rst ATG, into the respective vectors. All
manipulations were performed according to standard procedures; the
details of the plasmid constructions are available upon request.
2.3. in vitro and in vivo binding assays
Glutathione-S-transferase (GST)-CDC6, GST deletion mutants of
CDC6 (GST-CDCdls) and GST were puri¢ed from Escherichia coli
BL21(DE3) transformed with pGEX-CDC6, pGEX-CDCdls and
pGEX-6P-1, respectively, as described previously [22]. 2 Wg of the
puri¢ed GST-CDC6, GST-CDCdls or GST was ¢rst applied to a
glutathione Sepharose 4B (Amersham-Pharmacia) in a bu¡er contain-
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ing 20 mM Tris^HCl (pH 8.0), 150 mM NaCl, 0.5% NP-40 and 1 mM
EDTA. Subsequently, 0.1 Wg c-Myc (released from maltose-binding
protein (MBP)-c-Myc expressed in E. coli, as described previously
[23,24]) was applied to the column. After extensive washing of the
column with the same bu¡er as that described above, the proteins
bound to the resin were recovered, separated in a 7.5% polyacryl-
amide gel containing sodium dodecyl sulfate (SDS), and blotted
against an anti-c-Myc monoclonal antibody, 9E10 [25]. Co-immuno-
precipitation was performed using human HL60 cell lysates in a lysis
bu¡er (20 mM Tris (pH 7.5), 150 mM NaCl, 0.2% NP-40, 2 mM
EDTA and 2 mM dithiothreitol (DTT)). After the cell extracts were
immunoprecipitated with the anti-c-Myc antibody, the antigen^anti-
body complexes were immobilized on protein-G-Sepharose for 30 min
at 4‡C and washed extensively with the lysis bu¡er ¢ve times. The
bound proteins were separated in a 7.5% polyacrylamide gel contain-
ing SDS, transferred onto a nitrocellulose membrane, and blotted
with an anti-CDC6 antibody (N-19, Santa Cruz).
2.4. Luciferase assay
HeLa cells in a 6 cm dish were transfected with 1 Wg of pCMV-L-
gal, 0.5 Wg of pEF-c-myc and various amounts of pCMV-CDC6-HA
or pCMV-T7-S6 [15] together with 2 Wg of p4xE-SVP-Luc by the
calcium phosphate method [26]. Two days after transfection, whole
cell extracts were prepared by addition of the Triton X-100-containing
solution from a Pica gene kit (Wako Pure Chemicals Co. Ltd., Kyoto,
Japan) to the cells. About one-¢fth volume of the extract was used for
the L-galactosidase assay to normalize the transfection e⁄ciencies as
described previously [22,27], and the luciferase activity due to the
reporter plasmid was determined.
2.5. Indirect immuno£uorescence
HeLa cells were transfected with pEF-c-myc together with pEF-
CDC6-HA by the calcium phosphate precipitation technique [26].
Forty-eight hours after transfection, the cells were ¢xed with a solu-
tion containing 4% paraformaldehyde and 1% Triton X-100, and they
were reacted with a mouse anti-c-Myc monoclonal antibody (9E10)
and a rabbit anti-HA polyclonal antibody (Y-11, Santa Cruz). The
cells were then reacted with a rhodamine- or FITC-conjugated anti-
mouse or anti-rabbit IgG, respectively, and observed under a confocal
laser £uorescent microscope.
2.6. Electrophoretic mobility shift assay
The binding reactions contained 0.5 ng of the radiolabeled E-box
sequence (5P-CCCCCACCACGTGGTGCCTGA-3P), 25 mM HEPES
(pH 7.5), 50 mM KCl, 5 mM MgCl2, 0.5 mM EDTA, 5% glycerol, 10
mM DTT, 0.1% NP-40, 0.5 mg/ml bovine serum albumin and the
indicated amount of protein. A reaction mixture (15 Wl) was incubated
at 20‡C for 20 min. The resulting protein^DNA complexes were re-
solved on 4% polyacrylamide gels containing 0.25UTBE (22.5 mM
Tris, 22.5 mM H3BO4 and 0.63 mM EDTA) at 4‡C.
3. Results and discussion
3.1. Interaction of c-Myc with CDC6 in vivo
We have previously reported that ORC1, a component of
ORCs in DNA replication, interacts with c-Myc and abro-
gates the E-box-dependent transactivation activity of c-Myc
by interfering with c-Myc^SNF5 interaction [15]. Since CDC6
is associated with an ORC complex, we examined the inter-
action between c-Myc and CDC6 under physiological condi-
tions. A whole cell extract of human HL60 cells was immu-
noprecipitated with an anti-c-Myc antibody or non-speci¢c
IgG, and the precipitate was blotted using an anti-CDC6 anti-
body (Fig. 1A). The CDC6 was detected in the precipitate
with the anti-c-Myc antibody but not in the precipitate with
non-speci¢c IgG (Fig. 1A, lanes 2 and 3). These results clearly
indicate that c-Myc is associated with CDC6 in cells.
3.2. Co-localization of c-Myc with CDC6 in cells
To determine the cellular localization of CDC6 and c-Myc,
expression vectors for CDC6-HA and c-Myc were co-trans-
fected into human HeLa cells. Two days after transfection, the
Fig. 1. Association of c-Myc and CDC6 in vivo. A: The extract of HL60 cells was prepared and subjected to an immunoprecipitation reaction
using an anti-c-Myc or non-speci¢c IgG (lanes 2 and 3, respectively). The precipitates were blotted with an anti-CDC6 monoclonal antibody.
The 1/100 amount of the cell extract used for the reactions (lane 1, Input) was analyzed in parallel. B: HeLa cells were transfected with pEF-c-
myc together with pEF-CDC6-HA by the calcium phosphate precipitation technique [26]. Forty-eight hours after transfection, the cells were
¢xed with a solution containing paraformaldehyde and Triton X-100, and they were reacted with a mouse anti-c-Myc monoclonal antibody
(9E10) and a rabbit anti-HA polyclonal antibody (Y-11, Santa Cruz). The cells were then reacted with a rhodamine- or FITC-conjugated anti-
mouse or anti-rabbit IgG, respectively, and observed under a confocal razor £uorescent microscope. The same cells were also stained with
DAPI.
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cells were stained with an anti-HA antibody and an anti-c-
Myc antibody, and further with FITC- and rhodamine-con-
jugated secondary antibodies, respectively. Cell nuclei were
also stained with DAPI. The results clearly showed that the
CDC6-HA (green) and c-Myc (red) co-localized in nuclei, as
shown by the yellow color (Fig. 1B).
3.3. Binding of c-Myc with CDC6 in vitro
Human CDC6 and its deletion mutants were expressed as
fusion proteins of GST and a⁄nity-puri¢ed by glutathione
Sepharose resin. Full-size c-Myc was ¢rst expressed as a fu-
sion protein to MBP, and prepared after cleavage of MBP by
PreScission protease as described previously [23,24]. Subse-
quently, an in vitro binding assay, the so-called pull-down
assay, was carried out by incubating GST-CDC6s and c-
Myc under a high (150 mM) salt condition on glutathione
Sepharose resin, and the bound protein(s) was detected by
Western blotting with an anti-c-Myc antibody (Fig. 2). c-
Myc possessed strong binding activity to wild-type CDC6
but not to GST (Fig. 2, lanes 2 and 3). As CDC6 contains
an NTP-binding domain at the central part spanning amino
acids #172^403 that is necessary for DNA replication activity,
the ¢ve segments of GST-CDC4, N(1^171), M(162^420),
C(404^560), NM(1^420) and MC(162^560), were prepared
and used for an in vitro binding assay to c-Myc. The N-ter-
minal segment, but not the segments containing the NTP-
binding domain, bound to c-Myc (Fig. 3, lanes 4^8), indicat-
ing that c-Myc binds to the N-terminal region of CDC6 span-
ning amino acids #1^172. To determine the CDC6-binding
region within c-Myc, various deletion constructs of c-Myc
were expressed in E. coli as MBP fusion proteins and puri¢ed.
MBP-c-Myc deletion mutants and GST-CDC6 (or GST-Max
as a control) were mixed, and in vitro binding assays were
carried out (Fig. 3). GST-Max and GST-CDC6 bound to
MBP-c-Myc deletion mutants, but there was no binding to
MBP itself (Fig. 3, lanes 4^27 and lanes 1^3, respectively).
GST-Max could not bind to MBP-c-Myc mutants lacking
the leucine zipper (Zip), N, M, HZ and LZ (Fig. 3B, lanes
7^12, 19^21 and 25^27). GST-CDC6 also showed the same
binding patterns as those of GST-Max, except for one of the
mutants, H1 (Fig. 3, lane 24). CDC6 does not bind to H1,
which lacks only the ¢rst helix, spanning amino acids #368^
382. These results indicate that CDC6 binds to the region
containing all of the basic, helix-loop-helix and leucine zippers
region of c-Myc.
3.4. Abrogation of E-box-dependent transcription activity
of c-Myc by CDC6
Both CDC6 and Max bound to the C-proximal region of c-
Myc. It is therefore possible that two proteins compete for
binding to c-Myc. To assess this possibility, an electrophoretic
mobility shift assay was carried out. Various combinations of
recombinant GST-c-Myc-C, GST, Max and CDC6 were in-
cubated with labeled oligonucleotides corresponding to the E-
box as a probe. No nucleoprotein complex was observed in
the incubation of the probe with CDC6 by itself, or with
GST-c-Myc-C or GST (Fig. 4A, lanes 8^10). The formation
of a Max/Max homodimer on the E-box probe was not af-
fected by the addition of excess amounts of CDC6 (Fig. 4A,
lanes 11^13). The c-Myc/Max heterodimer, on the other hand,
was decreased by the addition of CDC6 in a dose-dependent
manner, with a concomitant increase of the Max/Max homo-
dimer (Fig. 4A, lanes 2^5). The results suggest that CDC6
interferes with the association between c-Myc and Max by a
competitive binding to c-Myc. Since c-Myc/Max recognizes
the E-box to stimulate gene expression [28], and since this
interaction is abrogated by CDC6 as described above, we
examined the e¡ect of CDC6 on the E-box-dependent tran-
scription activity of c-Myc. Luciferase activity was examined
in HeLa cells transfected with 0.5 Wg expression vector for c-
Myc and 4xE-box-SVP-Luc, with or without expression vec-
tors for CDC6. As a control, we also used an expression
vector for the dominant-negative S6 fragment of SNF5, a
component of the chromatin remodeling complex necessary
for c-Myc transcription activity [11]. The results are shown
in Fig. 4B. In the presence of an ‘empty vector’ (negative
control), c-Myc bound to the E-box in the reporter plasmid
and thereby activates the expression of luciferase. As previ-
Fig. 2. In vitro binding activity of c-Myc and CDC6. GST fusion proteins of CDC6 and its various fragments were expressed as GST fusion
proteins in E. coli and puri¢ed. MBP-c-Myc was also prepared as above and digested with PreScission protease to yield MBP-free c-Myc. The
GST fusion proteins, or GST alone, were applied to the glutathione beads and incubated with c-Myc. After extensive washing, the proteins
that had bound to the beads were analyzed in an SDS-containing polyacrylamide gel (7.5%) and blotted with an anti-c-Myc antibody (C-33,
Santa Cruz). One-twentieth volume of the c-Myc used for the binding reaction was applied to the same gel (lane 1).
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ously reported [11], the S6 fragment of SNF5 inhibited the E-
box-dependent transcription in a dose-dependent manner. As
for CDC6, it inhibited E-box-dependent luciferase expression
in a manner similar to that of the S6 fragment (Fig. 4B).
These results clearly indicate that CDC6 and Max are func-
tionally competitive in the transcriptional activity of c-Myc.
In this study, we have found that (1) c-Myc interacts with
CDC6 in vitro and in vivo, (2) the two proteins co-localize in
HeLa cell nuclei, and (3) this complex inhibits E-box-depen-
dent transcription by abrogating Max binding to c-Myc. This
is the ¢rst report of CDC6 having a function in the modula-
tion of transcription.
CDC6 is known to be a DNA replication factor necessary
for forming a pre-replication complex [29^32]. An ORC ¢rst
binds to the origin of DNA replication in the genome, then
CDC6 makes contact with the ORC, and ¢nally an MCM
complex is recruited by the ORC^CDC6 complex to allow
the initiation of DNA replication. In addition to this function
in DNA replication, ORC and MCM have also been reported
to play a role in transcription. On one hand, ORC is known
to bind chromatin and to inhibit the transcription, and/or to
remodel the chromatin structure in yeast and Drosophila cells
[16^20]. On the other hand, MCM enhances the transcription
activity of STAT-1K [33] and associates with RNA polymer-
ase II holoenzyme in human cells [34]. Furthermore, CDC6,
like ORC1 and like c-Myc itself, binds tightly to the chroma-
tin during some stage of the cell cycle [32]. It is therefore not
unreasonable to assume that CDC6 also has a transcription
activity-linked c-Myc.
Many proteins that bind to the C-proximal region of c-Myc
have been identi¢ed. These include Max [28,35,36], YY1 [37],
Miz-1 [38], Nmi [39], BRCA1 [40], CBF/NF-Y [23], AP2 [41],
cdr2 [42], SNF5 [11], MSSP [24] and ORC1 [15]. YY1, SNF5,
MSSP and ORC1 have been reported to act as modulators of
the transcriptional activity of c-Myc; all of the proteins except
for SNF5 inhibit it. SNF5 is a component of the chromatin
remodeling complex and ties c-Myc/Max with the basal tran-
scription factors or with other chromatin remodeling proteins
Fig. 3. Determination of the binding region of c-Myc with CDC6. The MBP or MBP fusion proteins of wild-type and various mutants of hu-
man c-Myc, schematically presented in the lower panel, were prepared in E. coli and incubated with glutathione beads coupled with GST-
CDC6 (A) or GST-Max (B). Proteins that had bound to the beads were then separated by SDS^PAGE (10%) and blotted using an anti-MBP
antibody (NEB). One-twentieth volume of the proteins used for binding reaction was applied to the same gel (I).
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possessing a histone acetyl transferase activity [11]. ORC1
competitively binds to c-Myc/Max and SNF5, thereby abro-
gating the transcription activity of c-Myc [15]. MSSP, a single-
strand binding protein [43], makes a ternary complex between
c-Myc and Max and this complex is released from the E-box
sequence, thereby inhibiting the transcription activity of c-
Myc [24]. We have found here that CDC6 competes directly
with Max for binding to c-Myc. The mechanism of the inhi-
bition of c-Myc transcription activity by CDC6 is therefore
di¡erent from those by ORC1 and MSSP.
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